Biosimilars are safe, effective alternatives to brand products
A biosimilar is a biologic that is highly similar to and has no clinically meaningful differences from a similar, FDA-approved biologic. Biosimilars are newer to the market but are typically less expensive than the reference brand product.
Ground yourself in biosimilar basics
Explore the differences in the regulatory pathways between generics and biosimilars.
Top 10 biosimilar acronyms
It’s okay not to know (or remember) all of the answers all of the time.
Getting biosimilars to market
Discover what works and what doesn’t when getting biosimilars to market.
Embracing upcoming Humira biosimilars
Long-awaited Humira biosimilars will enter the market in 2023 as some of the first biosimilars processed on the pharmacy benefit. Prime is developing an adoption strategy with our clients to drive cost savings while promoting member health.
A PCMA podcast: Understanding the value of biosimilars
Host JC Scott leads a discussion on strategies to increase the use of biosimilars and drive lower specialty drug costs. He’s joined by Dr. Joseph Leach, Prime’s Senior Vice President and Chief Medical Officer and Jarrod Henshaw, Prime’s Senior Vice President and Innovation & Supply Chain Officer.
Converting a drug class to biosimilars
In Prime’s case study, three Blue plans added biosimilars to their formularies and preferred them, which collectively delivered a savings of $4 million. If all of Prime’s Blue Plan clients did the same and adoption rates followed, we project savings of $41-$55 million per year.
This comprehensive solution leverages the collective strength of Prime’s client membership to help control medical costs by including biosimilars, medical rebates and low net cost savings.
November 3, 2021
EAGAN, Minn. – Prime Therapeutics LLC (Prime), a leading pharmacy benefit manager (PBM)…
October 15, 2021
MILI and Prime Therapeutics leadership led a virtual panel discussion on Oct. 13,…
In the news
December 6, 2021
1 U.S. Food and Drug Administration, and Federal Trade Commission. (2020, February 3). FDA and FTC Announce New Efforts to Further Deter Anti-Competitive Business Practices, Support Competitive Market for Biological Products to Help Americans [Press release]. https://www.fda.gov/news-events/press-announcements/fda-and-ftc-announce-new-efforts-further-deter-anti-competitive-business-practices-support
2 Cardinal Health. (2022, June 13). Humira® biosimilar landscape overview. https://www.cardinalhealth.com/en/product-solutions/pharmaceutical-products/biosimilars/humira-biosimilar-landscape-overview.html